CHESTER LANE LEACH
Pilots at Coyote Cyn Trl, Sedillo, NM
License number
New Mexico A1097819
Issued Date
Jul 2016
Expiration Date
Jul 2018
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
7 Coyote Canyon Trl, Sedillo, NM 87059
Professional information
Chemically Modified Small Molecules
US Patent:
2006018, Aug 17, 2006
Filed:
Jan 30, 2006
Appl. No.:
11/344404
Inventors:
C. Fishburn - Redwood City CA, US
Tacey Viegas - Madison AL, US
Mei-Chang Kuo - Palo Alto CA, US
Yuan Song - Belmont CA, US
Hema Gursahani - Foster City CA, US
Chester Leach - Tijeras NM, US
Tacey Viegas - Madison AL, US
Mei-Chang Kuo - Palo Alto CA, US
Yuan Song - Belmont CA, US
Hema Gursahani - Foster City CA, US
Chester Leach - Tijeras NM, US
International Classification:
A61K 9/14, A61L 9/04
US Classification:
424046000
Abstract:
Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
Chemically Modified Small Molecules
US Patent:
2012008, Apr 12, 2012
Filed:
Oct 11, 2011
Appl. No.:
13/271158
Inventors:
C. Simone Fishburn - Redwood City CA, US
Tacey Viegas - Madison AL, US
Mei-Chang Kuo - Palo Alto CA, US
Yuan Song - Belmont CA, US
Hema Gursahani - Foster City CA, US
Chester Leach - Tijeras NM, US
Tacey Viegas - Madison AL, US
Mei-Chang Kuo - Palo Alto CA, US
Yuan Song - Belmont CA, US
Hema Gursahani - Foster City CA, US
Chester Leach - Tijeras NM, US
International Classification:
A61K 31/16, C07D 489/08, C07C 43/13, C07J 5/00, A61K 31/573, C07C 233/21, A61K 31/485
US Classification:
514180, 564123, 514613, 546 44, 514282, 552576, 568625
Abstract:
Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.
Chemically Modified Small Molecules
US Patent:
8067431, Nov 29, 2011
Filed:
Feb 22, 2010
Appl. No.:
12/710167
Inventors:
C. Simone Fishburn - Redwood City CA, US
Tacey Viegas - Madison AL, US
Mei-Chang Kuo - Palo Alto CA, US
Yuan Song - Belmont CA, US
Hema Gursahani - Foster City CA, US
Chester Leach - Tijeras NM, US
Tacey Viegas - Madison AL, US
Mei-Chang Kuo - Palo Alto CA, US
Yuan Song - Belmont CA, US
Hema Gursahani - Foster City CA, US
Chester Leach - Tijeras NM, US
Assignee:
Nektar Therapeutics - San Francisco CA
International Classification:
A61K 31/485, C07D 489/08
US Classification:
514282, 546 44
Abstract:
Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1. 5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.